Target intelligence / Profile preview

RNA binding motif protein 24 (RBM24)

Target
RBM24
Molecular classification
RNA-binding protein, Splicing regulator, Post-transcriptional regulator, Other
01

Overview

RBM24 is a single-domain RNA binding protein containing an RNA Recognition Motif (RRM) at its N-terminus, which preferentially binds GU-rich sequences in target mRNAs. It is strongly and dynamically expressed in specific tissues, especially cardiac and skeletal muscle, and developmental sensory structures. RBM24 is essential for proper alternative splicing of muscle and heart genes, such as ACTN2, TTN, MYH6, and MYBPC3, and for cytoplasmic polyadenylation of lens mRNAs. It also regulates mRNA stability, including p21, p63, and SLC7A11, affecting cell cycle progression, apoptosis, and protection against ferroptosis. Mutations or deficiency in RBM24 are linked to congenital muscle, heart, and sensory disorders in animal models, and its downregulation is associated with certain human cancers. Although no direct drugs currently target RBM24, its molecular pathways present potential opportunities for therapeutic intervention.

Other names
RNA-binding protein 24RNPC6FLJ30829dJ259A10.1RNA-binding region-containing protein 6RNA-binding region (RNP1, RRM) containing 6
02

Mechanism of action

Modulation of mRNA splicing, stability, and translation; Protection against ferroptosis by stabilizing SLC7A11 mRNA; Interaction with translation initiation factor eIF4E to modulate p53 translation

03

Biological functions

Alternative splicing of mRNARegulation of mRNA stabilityCytoplasmic polyadenylationCell differentiation (cardiac, skeletal muscle, lens, sensory organs)Cell cycle regulationModulation of ferroptosis and inflammatory response
04

Disease associations

Cardiovascular disease (congenital heart defects, cardiomyopathy)Neuromuscular disorders (myopathy)Ocular disease (blindness, lens development)InflammationLiver steatosisCancer (expression alterations reported in glioblastoma and glioma, possible roles in tumorigenesis and therapy resistance)
05

Safety considerations

RBM24 deficiency is embryonic lethal in mice due to heart development defectsDysregulation may cause muscle, sensory, or cardiac disordersChronic inflammation and liver steatosis observed in knockout models
06

Interacting drugs

Rosiglitazone
07

Biomarkers

Reduced RBM24 expression (e.g., in gliomas) may serve as a biomarker for disease presence or progressionSLC7A11 mRNA levels may serve as an efficacy biomarker for ferroptosis studies

Beyond the preview

Go deeper on RNA binding motif protein 24 (RBM24).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA binding motif protein 24 (RBM24).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call